Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study
| dc.contributor.author | Ferlazzo, G | |
| dc.contributor.author | Mohr, E | |
| dc.contributor.author | Laxmeshwar, C | |
| dc.contributor.author | Hewison, C | |
| dc.contributor.author | Hughes, J | |
| dc.contributor.author | Jonckheere, S | |
| dc.contributor.author | Khachatryan, N | |
| dc.contributor.author | De Avezedo, V | |
| dc.contributor.author | Egazaryan, L | |
| dc.contributor.author | Shroufi, A | |
| dc.contributor.author | Kalon, S | |
| dc.contributor.author | Cox, H | |
| dc.contributor.author | Furin, J | |
| dc.contributor.author | Isaakidis, P | |
| dc.date.accessioned | 2018-03-09T15:47:19Z | |
| dc.date.available | 2018-03-09T15:47:19Z | |
| dc.date.issued | 2018-02-13 | |
| dc.date.submitted | 2018-02-22 | |
| dc.identifier.citation | Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. 2018 Lancet Infect Dis | en |
| dc.identifier.issn | 1474-4457 | |
| dc.identifier.pmid | 29452942 | |
| dc.identifier.doi | 10.1016/S1473-3099(18)30100-2 | |
| dc.identifier.uri | http://hdl.handle.net/10144/619082 | |
| dc.description.abstract | Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa. | |
| dc.language.iso | en | en |
| dc.publisher | Elsevier | en |
| dc.rights | Archived with thanks to The Lancet. Infectious Diseases | en |
| dc.title | Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study | en |
| dc.identifier.journal | The Lancet. Infectious Diseases | en |
| refterms.dateFOA | 2019-03-04T13:46:14Z | |
| html.description.abstract | Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa. |
